Table II.
Dose-dependent apoptotic effect of ABT-88 on melanoma cell lines.
| Apoptotic cells (Q2+Q4)
|
|||||
|---|---|---|---|---|---|
| CTRL | 5 µM | 10 µM | 25 µM | 50 µM | |
| COPA-159 | 8.2+0.01 | 19.4+0.08 | 31.3+0.02a | 54.2+0.14a | 76.2+0.16b |
| LCP | 6.2+0.07 | 39.6+0.11a | 58.1+0.16a | 78.9+0.11b | 92.6+0.08b |
| M638 | 6.7+0.02 | 17.5+0.13 | 10.9+0.05 | 49.9+0.02a | 84.5+0.12b |
| 397-MEL | 2.4+0.12 | 23.1+0.04a | 24.2+0.07a | 58+0.04b | 81.5+0.07b |
| SK-MEL-5 | 9.9+0.08 | 13.2+0.05 | 10.2+0.04 | 24.2+0.05a | 34.1+0.01a |
| SK-MEL-2 | 8.5+0.13 | 13.9+0.11 | 13.3+0.04 | 30+0.13a | 30.7+0.03a |
| M14 | 3.2+0.12 | 30.4+0.14a | 50.3+0.16a | 66.8+0.08b | 73.6+0.05b |
| LOX-IMVI | 7.7+0.01 | 12.1+0.06a | 7.8+0.08 | 33.3+0.12a | 49.9+0.12a |
Flow cytometric assessment of late (Q2) and early (Q4) apoptosis of melanoma cells after 72 h treatment with ABT-888. Treated cells with increasing concentration of ABT-888 were stained with Annexin V-FITC and propidium iodide. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance calculated against the CTRL (aP<0.05 and bP<0.01).